Molecular structure of Spebrutinib, CAS Number: 1202757-89-8
Spebrutinib (CAS 1202757-89-8)
Alternate Names:
AVL-292 AVL292 AVL 292 cc-292 CC-292 Btk inhibitor CC-292
CAS Number:
1202757-89-8
Molecular Weight:
423.40
Molecular Formula:
C22H22FN5O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Spebrutinib (CAS 1202757-89-8) References
- Emerging immunological drugs for chronic lymphocytic leukemia. | Robak, P., et al. 2015. Expert Opin Emerg Drugs. 20: 423-47. PMID: 26153226
- Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. | Barf, T., et al. 2017. J Pharmacol Exp Ther. 363: 240-252. PMID: 28882879
- A highly sensitive LC-MS/MS method to determine novel Bruton's tyrosine kinase inhibitor spebrutinib: application to metabolic stability evaluation. | Abdelhameed, AS., et al. 2019. R Soc Open Sci. 6: 190434. PMID: 31312501
- Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors. | Zhai, Z., et al. 2019. Bioorg Med Chem. 27: 4124-4142. PMID: 31395509
- Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study. | Schafer, PH., et al. 2020. Rheumatol Ther. 7: 101-119. PMID: 31721017
- Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma. | Tanaka, H., et al. 2020. Leuk Res. 88: 106286. PMID: 31865062
- The TKI Era in Chronic Leukemias. | De Novellis, D., et al. 2021. Pharmaceutics. 13: PMID: 34959482
- Development of novel hydrazidoarylaminopyrimidine-based BTK/FLT3 dual inhibitors with potent in vivo anti-hematological malignancies effects. | Ran, F., et al. 2023. Eur J Med Chem. 245: 114913. PMID: 36399923
- Design, synthesis and pharmacological characterization of aminopyrimidine derivatives as BTK/FLT3 dual-target inhibitors against acute myeloid leukemia. | Ran, F., et al. 2023. Bioorg Chem. 134: 106479. PMID: 36989958
- Discovery of Novel Potent and Fast BTK PROTACs for the Treatment of Osteoclasts-Related Inflammatory Diseases. | Huang, J., et al. 2024. J Med Chem. 67: 2438-2465. PMID: 38321747
Inhibitor of:
ACSL, ACSL4, Btk, CD200R4, Ig λ chain, TNF receptor superfamily (TNFRSF), and ZAP-70.Activator of:
IL-5, and Tec.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Spebrutinib, 100 mg | sc-507524 | 100 mg | $375.00 |